HPLC-MS/MS methods for the quantitative analysis of 5-oxoproline (pyroglutamate) in rat plasma and hepatic cell line culture medium

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 3, 2011, Pages 655-663

  Geenen, Suzanne ^a,b   Guallar Hoyas, Cristina ^b,e   Michopoulos, Filippos ^b   Kenna, J Gerry ^b   Kolaja, Kyle L ^c   Westerhoff, Hans V ^a,d   Thomas, Paul ^e   Wilson, Ian D ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c HOFFMANN LA ROCHE INC   (United States)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e LOUGHBOROUGH UNIVERSITY   (United Kingdom)

Author keywords

5 Oxoproline; Glutathione; Hepatotoxicity; Oxidative stress; Pyroglutamate

Indexed keywords

BIOLOGICAL MARKER; BROMOBENZENE; CHLORPROMAZINE; CYTOCHROME P450 2E1; ETHIONINE; GLUTATHIONE; METHAPYRILENE; PARACETAMOL; PYROGLUTAMIC ACID; STREPTOMYCIN;

ACCURACY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG BLOOD LEVEL; EPITHELIUM CELL; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER INJURY; LIVER TOXICITY; MALE; MASS SPECTROMETRY; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; BIOLOGICAL MARKERS; CALIBRATION; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CULTURE MEDIA; DRUG-INDUCED LIVER INJURY; EPITHELIAL CELLS; HUMANS; LIVER; MALE; PYRROLIDONECARBOXYLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 79961128911     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.06.001     Document Type: Article

References (28)

1. Antoine D.J., Williams D.P., Park B.K. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin. Drug Metab. Toxicol. 2008, 4:1415-1427.
2. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 2005, 4:489-499.
3. Mitchell J.R., Jollow D.J., Potter W.Z., Davis D.C., Gillette J.R., Brodie B.B. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 1973, 187:185-194.
4. Wagren J.L., Mitchell M.D., Thompson D.C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 2005, 35:325-361.
5. Kalgutkar A.S., Soglia J.R. Minimising the potential for metabolic activation in drug discovery. Expert Opin. Drug Metab. Toxicol. 2005, 1:91-142.
6. Soga T., Baran R., Suematsu M., Ueno Y., Ikeda S., Sakurakawa T., Kakazu Y., Ishikawa T., Robert M., Nishioka T., Tomita M. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. 2006, 281:16768-16776.
7. Geenen S., Michopoulos F., Kenna J.G., Kolaja K.L., Westerhoff H.V., Wilson I. HPLC-MS/MS methods for the quantitative analysis of ophthalmic acid in rodent plasma and hepatic cell line culture medium. J. Pharm. Biomed. Anal. 2011, 54:1128-1135.
8. Ghauri F.Y., McLean A.E., Beales D., Wilson I.D., Nicholson J.K. Induction of 5-oxoprolinuria in the rat following chronic feeding with N-acetyl 4 aminophenol (paracetamol). Biochem. Pharmacol. 1993, 46:953-957.
9. Waters N.J., Waterfield C.J., Farrant R.D., Holmes E., Nicholson J.K. Integrated metabonomic analysis of bromobenzene-induced hepatotoxicity: novel induction of 5-oxoprolinosis. J. Proteome Res. 2006, 5:1448-1459.
10. Skordi E., Yap I.K.S., Claus S.P., Martin F.-P.J., Clorarec O., Lindberg J., Schuppe-Koistinen I., Holmes E., Nicholson J.K. Analysis of time-related metabolic fluctuations induced by ethionine in the rat. J. Proteome Res. 2007, 6:4572-4581.
11. Ghauri F.Y.K., Parkes H.G., Wilson I.D., Nicholson J.K. Asymptomatic 5-oxoprolinuria detected by proton magnetic resonance spectroscopy. Clin. Chem. 1993, 39:1341.
12. Meister A. 5-Oxoprolinuria (pyroglutamic aciduria) and other disorders of the γ-glutamyl cycle. The Inherited Basis of Metabolic Disease 1983, McGraw-Hill Book Co., New York.
13. Ristoff E., Larsson A. Patients with genetic defects in the γ-glutamyl cycle. Chem.-Biol. Intract. 1998, 111:113-121.
14. Creer M.H., Lau B.W., Jones J.D., Chan K.M. Pyroglutamic acidemia in an adult patient. Clin. Chem. 1989, 35:684-686.
15. Pitt J.J., Hauser S. Transient 5-oxoprolinuria and high anion gap metabolic acidocis: clinical and biochemical findings in eleven subjects. Clin. Chem. 1998, 44:1497-1503.
16. Duewall J.L., Fenves A.Z., Richey D.S., Tran L.D., Emmett M. 5-Oxoproline (pyroglutamic) acidocis associated with chronic acetaminophen use. Proc. Bayl. Univ. Med. Cent. 2010, 23:19-20.
17. Fortier G., Tenaschuk D., Mckenzie S.L. Capillary gas chromatography micro-assay for pyrogluatamic, glutamic and aspartic acids and glutamine and asparagines. J. Chromatogr. 1986, 361:252-261.
18. Shih F.F. Analysis of glutamine, glutamic acid and pyroglutamic acid in protein hydrolysates by high-performance liquid chromatography. J. Chromatogr. 1985, 322:248-256.
19. Friesen R.W., Novak E.M., Hasman D., Innis S.M. Relationship of dimethylglycine, choline, and betaine with oxoproline in plasma of pregnant women and their newborn infants. J. Nutr. 2007, 137:2641-2646.
20. Eckstein J.A., Ammerman G.M., Reveles J.M., Ackermann B.L. Analysis of glutamine, glutamate, pyroglutamate, and GABA in cerebrospinal fluid using ion pairing HPLC with positive electrospray LC/MS/MS. J. Neurosci. Methods 2008, 71:190-196.
21. Qu J., Chen W., Luo G., Wang Y., Xiao S., Ling Z., Chen G. Rapid determination of underivatized pyroglutamic acid, glutamic acid, glutamine, and other relevant amino acids in fermentation media by LC-MS-MS. Analyst 2002, 127:66-69.
22. Greer M.L., Barber J., Eakins J., Kenna J.G. Cell based approaches for evaluation of drug-induced liver injury. Toxicology 2010, 268:125-131.
23. Viswanathan C.T., Bansai S., Booth B., Stefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 2007, 24:1962-1973.
24. Lu S.C. Regulation of glutathione synthesis. Mol. Aspects Med. 2009, 30:42-59.
25. Waring J.F., Ulrich R.G., Flint N., Morfitt D., Kalkuhl A., Staedtler F., Lawton M., Beekman J.M., Suter L. Interlaboratory evaluation of rat hepatic gene expression changes induced by methapyrilene. Environ. Health Perspect. 2004, 112:439-448.
26. Hamadeh H.K., Knight B.L., Haugen A.C., Sieber S., Amin R.P., Bushel P.R., Stoll R., Blanchard K., Jayedev S., Tennant R.W., Cunningham M.J., Afshari C.A., Paules R.S. Methapyrilene toxicity: anchorage of pathologic observations to gene expression alterations. Toxicol. Pathol. 2002, 30:470-482.
27. Graham E.E., Walsh R.J., Hirst C.M., Maggs J.L., Martin S., Wild M.J., Wilson I.D., Harding J., Kenna J.G., Peter R.M., Williams D.P., Park K.B. Identification of the thiophene ring of methapyrilene as a novel bioactivation-dependent hepatic toxophore. J. Pharmacol. Exp. Ther. 2008, 362:657-671.
28. Mercer A.E., Regan S.L., Hirst C.M., Graham E.E., Antoine D.J., Benson C.A., Williams D.P., Foster J., Kenna J.G., Park B.K. Functional and toxicological consequences of metabolic bioactivation of methapyrilene via thiophene S oxidation: induction of cell defence, apoptosis and hepatic necrosis. Toxicol. Appl. Pharmacol. 2009, 239:297-305.